Table 1.
Baseline patient characteristics
| Variables | Overall | Group I | Group II | Group III | P value |
|---|---|---|---|---|---|
| All patients | 95 (100) | 42 (44.2) | 17 (17.9) | 36 (37.9) | — |
| Age (y) | |||||
| Mean ± SD | 67.9 ± 7 | 66.5 ± 7.6 | 68.7 ± 5.1 | 69.2 ± 7 | .479∗ |
| Median (range) | 69 (46–85) | 68 (46–77) | 69 (58–77) | 69.5 (58–85) | |
| Body mass index | |||||
| Mean ± SD | 24.4 ± 2.7 | 24.6 ± 2.9 | 23.4 ± 2.8 | 24.5 ± 2.3 | .390∗ |
| Median (range) | 24.4 (18.1–32) | 24.5 (19.7–31.1) | 24.1 (18.1–28.4) | 24.3 (20.1–32) | |
| Diabetes mellitus | 15 (15.8) | 10 (23.8) | 2 (11.8) | 3 (8.3) | .154† |
| Hypertension | 42 (44.2) | 20 (47.6) | 6 (35.3) | 16 (44.4) | .688† |
| Tuberculosis | 10 (10.5) | 7 (16.7) | 2 (11.8) | 1 (2.8) | .135† |
| Hepatitis | 4 (4.2) | 3 (7.1) | 0 (0.0) | 1 (2.8) | .401† |
| Prostate-specific antigen | |||||
| Mean ± SD | 9.7 ± 7.3 | 10.6 ± 8.5 | 10 ± 6.4 | 8.4 ± 5.9 | .685∗ |
| Median (range) | 7.6 (0.1–50.8) | 7.7 (3.5–50.8) | 7.7 (4.5–28.2) | 7.6 (0.1–35.3) | |
| Clinical stage | |||||
| T2a | 20 (21.1) | 13 (31.0) | 3 (17.6) | 4 (11.1) | .039† |
| T2b | 2 (2.1) | 2 (4.8) | 0 (0.0) | 0 (0.0) | |
| T2c | 73 (76.8) | 27 (64.3) | 14 (82.4) | 32 (88.9) | |
| Biopsy Gleason score sum | |||||
| 4–6 | 36 (37.9) | 10 (23.8) | 5 (29.4) | 21 (58.3) | .028† |
| 7 | 56 (58.9) | 30 (71.4) | 12 (70.6) | 14 (38.9) | |
| 8 | 2 (2.1) | 1 (2.4) | 0 (0.0) | 1 (2.8) | |
| Nerve sparing | |||||
| Unilateral | 33 (34.7) | 12 (28.6) | 8 (47.1) | 13 (36.1) | .392† |
| Bilateral | 62 (65.3) | 30 (71.4) | 9 (52.9) | 23 (63.9) |
∗
By Kruskal-Wallis test.
†
By χ2 test.